



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/531,747	04/18/2005	Peggy E. Hellberg	2395 US F	3474
7590 Alcon Research 6201 South Freeway Fort Worth, TX 76134		12/08/2009		
EXAMINER				
HUANG, GIGI GEORGIANA				
ART UNIT		PAPER NUMBER		
1612				
MAIL DATE		DELIVERY MODE		
12/08/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/531,747

Applicant(s)

HELLBERG, PEGGY E.

Examiner

GIGI HUANG

Art Unit

1612

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on 7/22/2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1 and 3 is/are pending in the application.
- 4a) Of the above claim(s) 3 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/CD)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Status of Application

1. The response filed July 22, 2009 has been received, entered and carefully considered. The response affects the instant application accordingly:
 - a. No claims have been amended.
 - b. Applicant's arguments are presented.
2. Claims 1 and 3 are pending in the case.
3. Claim 1 is present for examination.
4. The text of those sections of title 35.U.S. Code not included in this action can be found in the prior Office action.
5. All grounds not addressed in the action are withdrawn or moot.

Response to Arguments

6. Claim 1 is rejected under 35 U.S.C. 103(a) as being unpatentable over Xiao (U.S. Pat. 7250514) in view of Clark et al. (U.S. Pat. 5464866).

Applicant's arguments filed 7/22/2009 have been fully considered but they are not persuasive. Applicant asserts that Xiao is directed to histone deacetylase inhibitors and Clark is directed to substituted hydrindanes which are completely different compounds, that one of skilled in the art would not necessarily have a reasonable expectation that a histone deacetylase inhibitor would be successful in treating diseases treated with a substituted hydrindane, and that diabetic retinopathy and neovascular glaucoma taught in Xiao is different than chronic glaucoma addressed in Clark. This is not persuasive as Xiao teaches that histone deacetylase inhibitors such as

suberoylanilidine hydroxamic acid (Col. 3 line 1-30), are useful in the treatment of ocular neovascularization such as diabetic retinopathy and neovascular glaucoma (Col. 29 line 49-65, Col.30 line 3 and 19). The argument that Clark is teaching substituted hydrindanes is not persuasive as Clark is merely used to show what are the known ophthalmic neovascularization conditions in the art which include not only chronic glaucoma as asserted by Applicant, but also includes diabetic retinopathy and neovascular glaucoma; and that one would affect these conditions by treating neovascularization, as addressed by the reference to the specific section of Clark (Col. 7 line 34-63) in the action. As a result, the use of histone deacetylase inhibitors such as suberoylanilidine hydroxamic acid taught by Xiao to be useful in the treatment of ocular neovascularization, specifically teaching diabetic retinopathy and neovascular glaucoma, Clark teaching that known retinal/choroidal neovascularization and corneal neovascularization conditions such as diabetic retinopathy, neovascular glaucoma, and chronic glaucoma can be treated by treating neovascularization; it would be obvious to one of skill in the art to treat other known ophthalmic neovascular conditions such as chronic glaucoma with histone deacetylase inhibitors such as suberoylanilidine hydroxamic acid with a reasonable expectation of success as Xiao's general teaching is for the treatment of ocular neovascularization with these inhibitors.

Accordingly, the rejection is maintained.

7. Claim 1 is provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 3 of copending Application No. 10/697135.

There is no terminal disclaimer and no arguments presented by Applicant.

Accordingly, the rejection is maintained.

Conclusion

8. Claim 1 is rejected.
9. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to GIGI HUANG whose telephone number is (571)272-9073. The examiner can normally be reached on Monday-Thursday 8:30AM-6:00PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Fredrick Krass can be reached on 571-272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

GH
/Zohreh A Fay/
Primary Examiner, Art Unit 1612